Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIOSTAT BIOLOGX is a human-derived, resorbable biologic tissue sealant (fibrin sealant) developed as part of the Biostat System for the treatment of chronic discogenic low back pain. The product is designed to be delivered intradiscally using a proprietary application system, with the aim of sealing painful disruptions in intervertebral discs, reducing inflammation, and enhancing tissue repair. Its mechanism involves modulation of fibrin within the disc space to promote healing. Developed by Spinal Restoration, Inc., it was evaluated in Phase III clinical trials for patients with single-level discogenic low back pain but did not meet primary efficacy endpoints compared to saline control. The therapy represents a minimally invasive alternative to surgery for patients with internal disc disruption.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fibrin sealant.